This is true. Menveo is a dog with a finite limit as to how much it can grow due to the fact that it needs to be reconstituted. Unlike vaccines like pentacel, that reconstitution can't be justified with shot savings or schedule convenience. Also, we're running up against the sanofi contracts and those are pretty entrenched. We were able to draw out some of that business for awhile but sanofi is getting more aggressive about contract compliance and it's getting harder to convince docs they can buy some Menveo while on their sanofi agreement. And, don't even get me started on Menactra's 9 month indication. I'm concerned about what the next six months really will be bringing our way.